sorafenib has been researched along with Desmoid in 19 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 9 (47.37) | 24.3611 |
| 2020's | 10 (52.63) | 2.80 |
| Authors | Studies |
|---|---|
| Ford, CN; Johns, MS; Lee, WM; Merritt, WT; Petrelli, NJ; Rhodes, L; Sheldon, Y; Thompson, M; Tiesi, GJ | 1 |
| Errani, C; Mavrogenis, AF; Takahama, T; Tanaka, Y; Tsukamoto, S | 1 |
| Al-Jazrawe, M; Alman, BA; Grünhagen, DJ; Sacchetti, A; Schut, AW; Sleijfer, S; Timbergen, MJM; Verhoef, C; Vriends, ALM; Wiemer, EAC | 1 |
| Barwad, A; Dhamija, E; Gamangatti, S; Gangadharaiah, BB; Garg, V; Rastogi, S; Upadhyay, A | 1 |
| Androutsakos, T; Apostolidi, EA; Griniatsos, J; Karamouzis, MV; Papadakos, SP; Pergaris, A; Sarantis, P; Sougioultzis, S; Vallilas, C | 1 |
| Le Deley, MC; Penel, N; Ryckewaert, T | 1 |
| Orbach, D; Penel, N; Ryckewaert, T | 1 |
| Davis, JT; Keskinyan, VS; Mater, DV; Robles, J; Thompson, M | 1 |
| Bishop, AJ; Ratan, R; Roland, CL | 1 |
| Al-Jahdhami, S; Burney, IA; Kakaria, AK | 1 |
| Azem, F; Fouks, Y; Goaz, S; Hasson, Y; Malcov, M; Sheiman, V | 1 |
| Benech, N; Saurin, JC; Walter, T | 1 |
| Fernández-Ruiz, I | 1 |
| Agaram, NP; Attia, S; Basch, E; Conry, RM; Deshpande, HA; Dueck, AC; Gounder, MM; Gupta, AA; Horvat, N; Lefkowitz, RA; Mahoney, MR; Maki, RG; Mazaheri, Y; Milhem, MM; Movva, S; Pishvaian, MJ; Ravi, V; Riedel, RF; Sabagh, T; Schwartz, GK; Schwartz, LH; Tap, WD; Van Tine, BA; Wright, JJ; Yamashita, R | 1 |
| Wrighton, KH | 1 |
| Kasper, B | 1 |
| Batte, K; Braggio, D; Casadei, L; Jin, F; Koller, D; Lev, D; Lopez, G; Pollock, RE; Siva, N; Strohecker, AM; Welliver, M; Zewdu, A | 1 |
| Ahn, L; Antonescu, CR; D'Adamo, DR; Gounder, MM; Hameed, M; Keohan, ML; Lefkowitz, RA; Maki, RG; Singer, S; Stout, K | 1 |
3 review(s) available for sorafenib and Desmoid
| Article | Year |
|---|---|
Clinical outcomes of medical treatments for progressive desmoid tumors following active surveillance: a systematic review.
Topics: Doxorubicin; Fibromatosis, Aggressive; Humans; Hydroxyurea; Imatinib Mesylate; Methotrexate; Sorafenib; Vinorelbine; Watchful Waiting | 2023 |
Emerging Role of Multikinase Inhibitors in Desmoid Tumor Management.
Topics: Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Fibromatosis, Aggressive; France; Humans; Neoplasms, Connective Tissue; Protein Kinase Inhibitors; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome | 2019 |
Desmoid Fibromatosis: Management in an Era of Increasing Options.
Topics: Antineoplastic Agents; Fibromatosis, Aggressive; Humans; Indazoles; Protein Kinase Inhibitors; Pyrimidines; Sorafenib; Sulfonamides; Watchful Waiting | 2021 |
2 trial(s) available for sorafenib and Desmoid
| Article | Year |
|---|---|
A cost analysis of sorafenib for desmoid tumors.
Topics: Aged; Costs and Cost Analysis; Fibromatosis, Aggressive; Humans; Medicare; Niacinamide; Phenylurea Compounds; Sorafenib; Treatment Outcome; United States | 2023 |
Sorafenib for Advanced and Refractory Desmoid Tumors.
Topics: Adolescent; Adult; Aged; Antineoplastic Agents; Double-Blind Method; Female; Fibromatosis, Aggressive; Follow-Up Studies; Humans; Kaplan-Meier Estimate; Male; Middle Aged; Progression-Free Survival; Sorafenib; Survival Rate; Young Adult | 2018 |
14 other study(ies) available for sorafenib and Desmoid
| Article | Year |
|---|---|
In desmoid-type fibromatosis cells sorafenib induces ferroptosis and apoptosis, which are enhanced by autophagy inhibition.
Topics: Annexin A5; Antineoplastic Agents; Apoptosis; Autophagy; Ferroptosis; Fibromatosis, Aggressive; Humans; Sorafenib | 2022 |
Efficacy and tolerability of sorafenib in desmoid-type fibromatosis: A need to review dose.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Alopecia; Antineoplastic Agents; Drug-Related Side Effects and Adverse Reactions; Female; Fibromatosis, Aggressive; Humans; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Sorafenib; Young Adult | 2023 |
Unusual Presentation of an Uncommon Malignancy: A 74-Year-Old Woman with Aggressive Fibromatosis of the Large Intestine Presenting as a Liver Mass and the Therapeutic Management.
Topics: Aged; Female; Fibromatosis, Aggressive; Humans; Liver Neoplasms; Sorafenib; Tamoxifen | 2023 |
[Systemic treatment for management of aggressive fibromatosis in both adult and children: Level of evidence and unsolved questions].
Topics: Adult; Age Factors; Antineoplastic Agents; Child; Clinical Trials, Phase II as Topic; Clinical Trials, Phase III as Topic; Cross-Over Studies; Fibromatosis, Aggressive; Humans; Indazoles; Methotrexate; Proof of Concept Study; Protein Kinase Inhibitors; Pyrimidines; Randomized Controlled Trials as Topic; Receptors, Vascular Endothelial Growth Factor; Sorafenib; Sulfonamides; Vinblastine | 2020 |
Combination therapy with sorafenib and celecoxib for pediatric patients with desmoid tumor.
Topics: Adolescent; Anti-Inflammatory Agents, Non-Steroidal; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Child; Cyclooxygenase 2; Fibromatosis, Aggressive; Humans; Magnetic Resonance Imaging; Male; Protein Kinase Inhibitors; Receptors, Platelet-Derived Growth Factor; Risk Factors; Sorafenib; Treatment Outcome | 2020 |
Complete Response to Sorafenib in Locally Recurrent Unresectable Aggressive Fibromatosis.
Topics: Fibromatosis, Aggressive; Humans; Neoplasm Recurrence, Local; Sorafenib | 2021 |
Fertility preservation and PGT-M in women with familial adenomatous polyposis-associated desmoid tumours.
Topics: Abdominal Neoplasms; Adenomatous Polyposis Coli; Adult; Antineoplastic Agents; Female; Fertility Preservation; Fibromatosis, Aggressive; Humans; Oocyte Retrieval; Pregnancy; Preimplantation Diagnosis; Retrospective Studies; Sorafenib; Young Adult | 2021 |
Desmoid Tumors and Celecoxib with Sorafenib.
Topics: Adenomatous Polyposis Coli; Adult; Antineoplastic Combined Chemotherapy Protocols; Celecoxib; Female; Fibromatosis, Aggressive; Humans; Magnetic Resonance Imaging; Middle Aged; Neoplasm Recurrence, Local; Niacinamide; Phenylurea Compounds; Sorafenib; Tomography, X-Ray Computed | 2017 |
Targeting PCSK9 to reduce residual risk in ACS.
Topics: Cholesterol, LDL; Fibromatosis, Aggressive; Humans; Proprotein Convertase 9; Sorafenib | 2019 |
Desmoid tumours stalled by sorafenib.
Topics: Clinical Trials, Phase III as Topic; Double-Blind Method; Fibromatosis, Aggressive; Humans; Magnetic Resonance Imaging; Progression-Free Survival; Randomized Controlled Trials as Topic; Sorafenib; Treatment Outcome; Tumor Burden | 2019 |
Desmoid Tumors Respond to Sorafenib.
Topics: Fibromatosis, Aggressive; Humans; Progression-Free Survival; Sorafenib | 2019 |
Desmoid tumor: A focus set on a challenging but understudied rare disease.
Topics: Autophagy; Fibromatosis, Aggressive; Humans; Rare Diseases; Sorafenib | 2019 |
Autophagy inhibition overcomes sorafenib resistance in S45F-mutated desmoid tumors.
Topics: Antineoplastic Agents; Autophagy; Female; Fibromatosis, Aggressive; Humans; Male; Sorafenib | 2019 |
Activity of Sorafenib against desmoid tumor/deep fibromatosis.
Topics: Adolescent; Adult; Benzenesulfonates; Female; Fibromatosis, Aggressive; Humans; Magnetic Resonance Imaging; Male; Middle Aged; Niacinamide; Phenylurea Compounds; Protein Kinase Inhibitors; Pyridines; Retrospective Studies; Sorafenib; Treatment Outcome; Watchful Waiting; Young Adult | 2011 |